23ANDME HOLDING CO. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4641 USD | +1.11% |
|
-3.89% | -49.20% |
| Sales 2024 * | 217M 297M | Sales 2025 * | 265M 362M | Capitalization | 224M 306M |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 1.03 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.85 x |
| P/E ratio 2024 * |
-0.42
x | P/E ratio 2025 * |
-0.79
x | Employees | 793 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.15% |
More Fundamentals
* Assessed data
More news
Latest transcript on 23andMe Holding Co.
More recommendations
More press releases
| 1 day | +1.11% | ||
| 1 week | -3.89% | ||
| Current month | -12.76% | ||
| 1 month | -4.86% | ||
| 3 months | -37.96% | ||
| 6 months | -37.47% | ||
| Current year | -49.20% |
1 week
0.44
0.51
1 month
0.350.62
Current year
0.350.96
1 year
0.352.21
3 years
0.3513.68
5 years
0.3518.16
10 years
0.3518.16
| Managers | Title | Age | Since |
|---|---|---|---|
Anne Wojcicki
FOU | Founder | 50 | 05-12-31 |
Joseph Selsavage
DFI | Director of Finance/CFO | 61 | 22-08-31 |
Joseph Arron
CTO | Chief Tech/Sci/R&D Officer | - | 21-11-29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Roelof Botha
BRD | Director/Board Member | 50 | 21-06-15 |
Richard Scheller
BRD | Director/Board Member | 70 | 21-06-15 |
Patrick Chung
BRD | Director/Board Member | 50 | 21-06-15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 2 M€ | -.--% | ||
| 0.02% | 237 M€ | +2.89% | - | |
| 0.02% | 7 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.4641 | +1.11% | 2,624,020 |
| 24-04-25 | 0.459 | -1.73% | 2,456,098 |
| 24-04-24 | 0.4671 | -5.39% | 2,969,166 |
| 24-04-23 | 0.4937 | +7.23% | 5,002,956 |
| 24-04-22 | 0.4604 | -4.66% | 5,746,101 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotes
23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customersâ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patientsâ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.
Calendar
2024-05-22
- Q4 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.4641
USD
Average target price
1.425
USD
Spread / Average Target
+207.05%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -49.20% | 224M | |
| -17.89% | 8.25B | |
| +39.20% | 3.57B | |
| -39.11% | 2.46B | |
| -8.06% | 2.46B | |
| -7.35% | 2.38B | |
| -12.61% | 1.81B | |
| -19.01% | 1.55B | |
| -40.66% | 1.21B | |
| +7.56% | 1.11B |
- Stock Market
- Equities
- ME Stock
